Search results
Results from the Tech24 Deals Content Network
In April 2019, following a large-scale ring-vaccination scheme in the DRC outbreak, the WHO published the preliminary results of its research, in association with the DRC's Institut National pour la Recherche Biomedicale, into the effectiveness of the ring vaccination program, stating that the rVSV-ZEBOV-GP vaccine had been 97.5% effective at stopping Ebola transmission, relative to no ...
rVSV-ZEBOV. VSV-EBOV or rVSV-ZEBOV, sold under the brand name Ervebo, is a vaccine based on the vesicular stomatitis virus which was genetically modified to express a surface glycoprotein of Zaire Ebola virus. [ 16][ 17] In November 2019, the European Commission granted a conditional marketing authorization. [ 18]
In December 2016, it was announced that an experimental Ebola vaccine produced by Merck was found to be "highly protective" against the virus after trial runs involving 11,000 people in Guinea. [187] Previously, a 2015 study in medical journal The Lancet reported that the vaccine was 100 percent effective after tests on 4000 people in Guinea ...
A stockpile of half-a-million Ebola vaccine doses was established by Gavi and other global health partners in 2019 for use in outbreaks of haemorrhagic fever, which has an average fatality rate of ...
The vaccine, developed by the pharmaceutical giant Merck, is known as Ervebo. It's the first human Ebola vaccine to be approved by the EU. Ervebo was first engineered by the Public Health Agency ...
A month ago the European Union issued marketing authorization for a vaccine to prevent the Ebola virus in adults, and now the FDA has approved it. While noting that Ebola cases in the US have been ...
Vaccine. There is a vaccine to prevent Ebola—the FDA approved the Ebola vaccine rVSV-ZEBOV, aka Ervebo, in late 2019. However, the vaccine only targets Zaire ebolavirus, which has caused the ...
cAd3-ZEBOV (also known as the NIAID/GSK Ebola vaccine or cAd3-EBO Z) was an experimental vaccine for two ebolaviruses, Ebola virus and Sudan virus, developed by scientists at GlaxoSmithKline (GSK) and tested by National Institute of Allergy and Infectious Disease (NIAID). [1] This vaccine is derived from a chimpanzee adenovirus, Chimp ...